齊春勝 高森 李會(huì)強(qiáng) 高衛(wèi)真
肺癌的治療是以手術(shù)、放療和化療為主的綜合治療,化療通過給予藥物以殺死腫瘤細(xì)胞,一般與手術(shù)和放療聯(lián)合使用。順鉑是一種常見的化療藥物,可通過使DNA發(fā)生交聯(lián),抑制癌細(xì)胞的DNA復(fù)制和轉(zhuǎn)錄,使腫瘤細(xì)胞停止生長(zhǎng)發(fā)生凋亡[1]。但臨床實(shí)際中,腫瘤細(xì)胞往往對(duì)化療藥物產(chǎn)生耐受,使治療失效。因此,查找腫瘤的耐藥機(jī)制,開發(fā)新的逆轉(zhuǎn)耐藥性的方法,對(duì)提高臨床患者的受益有十分重要的意義。目前的研究[2,3]顯示,腫瘤細(xì)胞產(chǎn)生耐藥的機(jī)制包括減少藥物的吸收,通過轉(zhuǎn)運(yùn)蛋白增加藥物的外排,通過谷胱甘肽系統(tǒng)對(duì)抗腫瘤藥物進(jìn)行解毒,凋亡途徑異常以減少腫瘤細(xì)胞的凋亡等。
異長(zhǎng)春花堿(Vinorelbine)是一種新型抗腫瘤藥,在一系列臨床前研究中發(fā)現(xiàn)其可抑制腫瘤細(xì)胞的生長(zhǎng),促進(jìn)細(xì)胞凋亡,抑制腫瘤轉(zhuǎn)移[4]。而異長(zhǎng)春花堿逆轉(zhuǎn)順鉑耐受肺癌細(xì)胞的作用尚未得到充分研究,本研究擬對(duì)其作用和分子機(jī)制進(jìn)行初步的探討。
1.1 主要試劑與儀器 人肺癌細(xì)胞系A(chǔ)549和A549/DDP購自中國(guó)科學(xué)院上海生命科學(xué)研究院生物化學(xué)與細(xì)胞生物學(xué)研究所;細(xì)胞培養(yǎng)基購自Gibco公司;異長(zhǎng)春花堿購自Sigma公司;順鉑購自Sigma公司;Rhodamine-123(Rh-123)購自Sigma公司;非放射性細(xì)胞增殖檢測(cè)法(MTS)試劑、real-time PCR試劑盒購自Promega公司;細(xì)胞凋亡檢測(cè)試劑盒購自BD Biosciences;抗MDR1(multidrug resistance protein 1)、Bcl-2、caspase-3/8、survivin、PTEN(Phosphatase and tensin homolog)和p-AKT單抗均購自SantaCruz公司;NF-κB、Twist和Snail的轉(zhuǎn)錄活性報(bào)告基因檢測(cè)試劑盒購自Promega;ECL免疫印跡底物試劑盒購自Millipore公司;流式細(xì)胞儀CaliburTM:BD公司;酶標(biāo)儀和PCR儀:Thermo公司。
1.2 細(xì)胞培養(yǎng) A549和A549/DDP培養(yǎng)于10 cm培養(yǎng)皿,37oC、5%CO2和飽和濕度的培養(yǎng)箱中,培養(yǎng)基為90%EMEM,10%胎牛血清(FBS)。0.25%胰酶-EDTA消化傳代,所有試驗(yàn)均采用對(duì)數(shù)生長(zhǎng)期細(xì)胞。
1.3 MTS法檢測(cè)異長(zhǎng)春花堿對(duì)A549細(xì)胞的抑制作用 取對(duì)數(shù)生長(zhǎng)期的轉(zhuǎn)染克隆細(xì)胞,以(2-3)×104個(gè)/mL接種到96孔微孔板中,100 μL/孔,培養(yǎng)過夜使細(xì)胞貼壁。向?qū)?yīng)試驗(yàn)孔加入0.1 μmol/L、1 μmol/L、5 μmol/L、10 μmol/L、50 μmol/L、100 μmol/L異長(zhǎng)春花堿,繼續(xù)培養(yǎng)24 h,吸去培養(yǎng)基,按照試劑盒說明書加入MTS試劑,最后用酶標(biāo)儀測(cè)定490 nm波長(zhǎng)下的OD值,并計(jì)算藥物對(duì)細(xì)胞的抑制率。抑制率=(1-實(shí)驗(yàn)組OD值/對(duì)照組OD值)×100%。以異長(zhǎng)春花堿濃度的對(duì)數(shù)為橫坐標(biāo),抑制率為縱坐標(biāo)作圖并擬合抑制曲線,50%抑制率所對(duì)應(yīng)的化合物濃度即為IC50值。
1.4 MTS法檢測(cè)異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞耐藥性的逆轉(zhuǎn)作用 取對(duì)數(shù)生長(zhǎng)期的轉(zhuǎn)染克隆細(xì)胞,以(2-3)×104個(gè)/mL接種到96孔微孔板中,100 μL/孔,培養(yǎng)過夜使細(xì)胞貼壁。向?qū)?yīng)試驗(yàn)孔加入0.1μmol/L、1 μmol/L、5 μmol/L、10 μmol/L、50 μmol/L、100 μmol/L 順鉑和1 μmol/L和5 μmol/L異長(zhǎng)春花堿,繼續(xù)培養(yǎng)72 h,吸去培養(yǎng)基,按照試劑盒說明書加入MTS試劑,最后用酶標(biāo)儀測(cè)定490 nm波長(zhǎng)下的OD值,并計(jì)算藥物對(duì)細(xì)胞的抑制率。抑制率=(1-實(shí)驗(yàn)組OD值/對(duì)照組OD值)×100%。以異長(zhǎng)春花堿濃度的對(duì)數(shù)為橫坐標(biāo),抑制率為縱坐標(biāo)作圖并擬合抑制曲線,50%抑制率所對(duì)應(yīng)的化合物濃度即為IC50值。逆轉(zhuǎn)倍數(shù)=異長(zhǎng)春花堿處理組A549/DDP細(xì)胞IC50值/異長(zhǎng)春花堿未處理組A549/DDP細(xì)胞IC50值。
1.5 流式細(xì)胞術(shù)檢測(cè)A549/DDP細(xì)胞內(nèi)Rh-123含量和細(xì)胞凋亡 取對(duì)數(shù)生長(zhǎng)期的腫瘤細(xì)胞,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,加入10 μmol/L Rh-123染液,培養(yǎng)1 h后收集細(xì)胞,調(diào)整細(xì)胞濃度至106/mL,以流式細(xì)胞儀檢測(cè)細(xì)胞中Rh-123的熒光強(qiáng)度(488 nm激發(fā)光),考察異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞中Rh-123含量的影響。
取對(duì)數(shù)生長(zhǎng)期的腫瘤細(xì)胞,經(jīng)10 μmol/L順鉑及1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,加入PI和Annexin V-FITC各20 μL,避光孵育15 min后收集細(xì)胞,調(diào)整細(xì)胞濃度至106/mL,以流式細(xì)胞儀檢測(cè)細(xì)胞中PI和FITC的熒光強(qiáng)度(488 nm激發(fā)光),考察異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞凋亡的影響。
1.6 Western blot法檢測(cè)A549/DDP細(xì)胞MDR1、Bcl-2、caspase-3/8、survivin、PTEN和p-AKT蛋白的表達(dá) 取對(duì)數(shù)生長(zhǎng)期的腫瘤細(xì)胞,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,收集細(xì)胞并裂解提取蛋白。BCA(bicinchoninic acid)法測(cè)定細(xì)胞裂解物的蛋白含量,取等量蛋白質(zhì)以12% SDS-PAGE法分離并轉(zhuǎn)移至醋酸纖維素膜上,以相應(yīng)的單克隆抗體室溫孵育4 h以檢測(cè)目標(biāo)蛋白。洗去一抗,以HRP連接的二抗室溫孵育2 h,洗滌后以ECL試劑盒顯示免疫反應(yīng)條帶。β-actin作為內(nèi)參。
1.7 Real-time PCR檢測(cè)A549/DDP細(xì)胞中MDR1、Bcl-2、survivin和PTEN的mRNA表達(dá)水平 取對(duì)數(shù)生長(zhǎng)期的腫瘤細(xì)胞,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,用Trizol法提取各組總RNA,用real-time PCR試劑盒進(jìn)行逆轉(zhuǎn)錄得到cDNA。MDR1上游引物序列:5'-AAAAAGATCAACTCGTACCACTC-3',下游引物序列:5'-GCACAAAATACACCAACAA-3';Bcl-2上游引物序列:5′-ACGGGGTGAACTGGGGGAGGA-3′,下游引物序列:5′-TGTTTGGGGCAGGCATGTTGACTT-3′;survivin上游引物序列:5′-ACAACCAAACCTCACACTACTG-3′,下游引物序列:5′-ATAGATCCCATTACAGACAGCG-3′;PTEN上游引物序列:5′-CTTTGTGCTGAAAGACATTATGAC-3′,下游引物序列:5′-GGCTTTGTCTTTATTTGCTTTGTC-3′;β-actin上游引物序列:5′-TGAGCGCGGCTACAGCTT-3′,下游引物序列:5′-TCCTTAATGTCACGCACGATTT-3′;94oC變性3 min后,按下述條件擴(kuò)增40個(gè)循環(huán):95oC 5 s,65oC 35 s,72oC 60 s,循環(huán)后72oC延伸5 min。
1.8 A549/DDP細(xì)胞中NF-κB、Twist和Snail核轉(zhuǎn)錄活性的檢測(cè) 根據(jù)試劑說明書的方法,每孔加入0.1 μg的NF-κB、Twist和Snail熒光報(bào)告質(zhì)粒和0.02 μg對(duì)照質(zhì)粒轉(zhuǎn)染細(xì)胞,繼續(xù)培養(yǎng)6 h,洗去未轉(zhuǎn)入細(xì)胞的質(zhì)粒,更換新鮮培養(yǎng)基,加入1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h,以Dual-GloTM Luciferase assay system對(duì)兩種螢光酶的活性進(jìn)行檢測(cè)。
1.9 統(tǒng)計(jì)學(xué)方法 實(shí)驗(yàn)數(shù)據(jù)以均數(shù)±標(biāo)準(zhǔn)差表示,使用SPSS 13.0軟件進(jìn)行分析。采用單因素方差分析(One-way ANOVA)進(jìn)行比較,以P<0.05表示差異具有統(tǒng)計(jì)學(xué)意義。
2.1 異長(zhǎng)春花堿增加A549/DDP細(xì)胞對(duì)順鉑的敏感性 MTS法檢測(cè)結(jié)果顯示,A549/DDP細(xì)胞經(jīng)異長(zhǎng)春花堿作用24 h后,細(xì)胞抑制率呈現(xiàn)劑量依賴性,1 μmol/L異長(zhǎng)春花堿抑制率為3.7%,5 μmol/L異長(zhǎng)春花堿抑制率為8.3%,分別為無毒濃度(細(xì)胞抑制率<5%)和低毒濃度(細(xì)胞抑制率<10%),故采用上述兩種濃度進(jìn)行實(shí)驗(yàn)(圖1)。A549/DDP細(xì)胞對(duì)順鉑的IC50為60.3 μmol/L,經(jīng)1 μmol/L和5 μmol/L 異長(zhǎng)春花堿作用后,A549/DDP細(xì)胞對(duì)順鉑的敏感性明顯升高,IC50分別為31.6 μmol/L和23.7 μmol/L(圖2),逆轉(zhuǎn)倍數(shù)(RF)分別為1.91倍和2.54倍(P<0.05),表明異長(zhǎng)春花堿可提高A549/DDP細(xì)胞對(duì)順鉑的敏感性。
圖 1 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞增殖的影響Fig 1 The effect of Vinorelbine on A549/DDP cells proliferation.There was an increased cell proliferation inhibition with different concentration of Vinorelbine treatment in A549/DDP cell lines, the IC50 was 35.7 μmol/L. Bars indicate SD, n=5.
圖 2 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞耐藥性的逆轉(zhuǎn)作用Fig 2 Reversal effect of Vinorelbine on A549/DDP cells drug resistance. There was an increased cell proliferation inhibition with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines, the the IC50 of A549 was 9.8 μmol/L, the IC50 of A549/DDP without Vinorelbine treatment was 60.3 μmol/L,IC50 of A549/DDP with 1 μmol/L Vinorelbine treatment was 31.6 μmol/L, IC50 of A549/DDP with 5 μmol/L Vinorelbine treatment was 23.7 μmol/L, the sensitivity of cancer cells to cisplatin was increased by 1.91- and 2.54-folds respectively.Bars indicate SD, n=5.
2.2 異長(zhǎng)春花堿提高A549/DDP細(xì)胞胞內(nèi)Rh-123濃度 促進(jìn)細(xì)胞凋亡試驗(yàn)結(jié)果顯示,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,A549/DDP細(xì)胞吸收熒光染料Rh-123的能力顯著提高,與0 μmol/L組相比,細(xì)胞內(nèi)Rh-123含量分別提高了1.93倍和2.95倍(圖3)。進(jìn)一步的研究發(fā)現(xiàn),1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,A549/DDP細(xì)胞凋亡比例明顯上升,與0 μmol/L組凋亡率11.4%相比,細(xì)胞凋亡率分別為25.7%和43.6%(圖4)。
2.3 異長(zhǎng)春花堿調(diào)節(jié)A549/DDP細(xì)胞MDR1、Bcl-2、survivin和caspase-3/8的表達(dá) 為研究異長(zhǎng)春花堿逆轉(zhuǎn)A549/DDP耐藥性,促進(jìn)凋亡的機(jī)制,我們研究了多種耐藥基因的表達(dá)。結(jié)果顯示,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,MDR1、Bcl-2、survivin和caspase-3/8在蛋白水平的表達(dá)均顯著下調(diào),MDR1的mRNA表達(dá)下調(diào)43.5%和25.8%,Bcl-2的mRNA表達(dá)下調(diào)57.3%和34.1%,survivin的mRNA表達(dá)下調(diào)37.6%和12.4%(圖5)。
2.4 異長(zhǎng)春花堿抑制Akt的磷酸化,上調(diào)PTEN表達(dá),下調(diào)NF-κB、Twist和Snail的轉(zhuǎn)錄活性 為研究異長(zhǎng)春花堿調(diào)節(jié)上述耐藥和凋亡相關(guān)蛋白的機(jī)制,我們重點(diǎn)研究了一些關(guān)鍵信號(hào)通路的變化。Western blot顯示,1 μmol/L和5 μmol/L異長(zhǎng)春花堿作用24 h后,腫瘤細(xì)胞Akt的磷酸化水平下降,PTEN蛋白表達(dá)上調(diào),PTEN的mRNA表達(dá)上調(diào)183.4%和154.2%,而用報(bào)告基因系統(tǒng)評(píng)價(jià)NF-κB、Twist和Snail這些轉(zhuǎn)錄因子的活性時(shí),結(jié)果顯示,這些因子的轉(zhuǎn)錄活性均明顯下降,與0 μmol/L組相比,NF-κB轉(zhuǎn)錄活性下降53.2%和34.5%,Twist轉(zhuǎn)錄活性下降61.4%和33.5%,Snail轉(zhuǎn)錄活性下降57.8%和18.7%(圖6),說明異長(zhǎng)春花堿逆轉(zhuǎn)A549/DDP細(xì)胞順鉑耐藥性可能通過上調(diào)PTEN表達(dá),抑制AKT/NF-κB信號(hào)路徑活性,進(jìn)而抑制下游轉(zhuǎn)錄因子Twist和Snail轉(zhuǎn)錄活性,進(jìn)一步調(diào)節(jié)下游基因表達(dá)。
圖 3 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞Rh-123蓄積的影響Fig 3 The effect of Vinorelbine on the intracellular accumulation of Rh-123 in A549/DDP cells. A: The fow cytometry results in the effect of Vinorelbine on intra-cellular Rh-123 content of A549/DDP cells. B: The graph of the effect of Vinorelbine on the mean fluorescence intensity of Rh-123 in A549/DDP cells. The the content of Rh-123 was elevated 1.93- and 2.95-folds with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines compared with 0μmol/L Vinorelbine treatment. Data presented are Mean±SD,bars indicate SD, n=3, *: compared to 0 μmol/L group,P<0.05.
圖 4 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞凋亡的影響Fig 4 The effect of Vinorelbine on the apoptosis of A549/DDP cells. A: The fow cytometry results in the effect of Vinorelbine on inducing apoptosis of A549/DDP cells. B: The graph of the effect of Vinorelbine on the cells apoptosis rate of A549/DDP cells. The apoptosis rate was elevated 2.25- and 3.82-folds with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines compared with 0 μmol/L Vinorelbine treatment. Data presented are Mean±SD,bars indicate SD, n=3, *: compared to 0 μmol/L group, P<0.05.
圖 5 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞多藥耐藥基因表達(dá)的影響Fig 5 The effect of Vinorelbine on the expression of drug resistance in A549/DDP cells. A: The effect of Vinorelbine on the protein expression of MDR1, Bcl-2, survivin and cleaved caspase-3/8 in A549/DDP cells. There was a downregulated expression of MDR, Bcl-2 and survivin,however, there was an upregulated expression of caspase-3/8 with Vinorelbine treatment. β-actin was as an internal control. B: The effect of Vinorelbine on the mRNA expression of MDR1, Bcl-2 and survivin in A549/DDP cells.Real-time assay showed that the mRNA expression of MDR1 was downregulated 43.5% and 25.8%, Bcl-2 was downregulated 57.3% and 34.1%, survivin was downregulated 37.6% and 12.4% with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines compared with 0 μmol/L Vinorelbine treatment. β-actin was as an internal control. Data presented are Mean±SD,bars indicate SD, n=5, *: compared to 0 μmol/L group, P<0.05.
圖 6 異長(zhǎng)春花堿對(duì)A549/DDP細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)路徑的影響Fig 6 The effect of Vinorelbine on the signal transduction in A549/DDP cells. A: The effect of Vinorelbine on the expression of p-Akt and PTEN in A549/DDP cells with Vinorelbine treatment. β-actin was as an internal control. B: The effect of Vinorelbine on the mRNA expression of PTEN in A549/DDP cells. The mRNA expression of PTEN was upregulated183.4% and 154.2% with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines compared with 0 μmol/L Vinorelbine treatment. β-actin was as an internal control. Data presented are Mean±SD, bars indicate SD, n=5, *:compared to 0 μmol/L group, P<0.05. C: The effect of Vinorelbine on the transcriptional activity of NF-κB, Twist and Snail in A549/DDP cells. The transcriptional activities of NF-κB was downregulated 53.2% and 34.5%, Twist was downregulated 61.4% and 33.5%, and Snail was downregulated 57.8% and 18.7% with 1 μmol/L and 5 μmol/L Vinorelbine treatment in A549/DDP cell lines compared with 0 μmol/L Vinorelbine treatment. Data presented are Mean±SD, bars indicate SD, n=5, *: compared to 0μmol/L group, P<0.05.
肺癌是最常見的惡性腫瘤之一,鉑類藥物是一類廣泛使用的化療藥物,在多種惡性腫瘤的治療中表現(xiàn)出很好的效果。但肺癌治療過程中腫瘤細(xì)胞發(fā)展出來的耐藥性,往往導(dǎo)致治療失敗,尋找可運(yùn)用于臨床抵抗耐藥性的新藥,是提高患者臨床受益的迫切需要。
腫瘤細(xì)胞對(duì)化療藥物產(chǎn)生耐受性的機(jī)制之一是過表達(dá)MDR1等多藥耐藥蛋白,增加藥物的外排,降低藥物在細(xì)胞內(nèi)蓄積和在藥靶部位的有效濃度[5-7]。在本研究中,我們發(fā)現(xiàn)異長(zhǎng)春花堿可增加A549/DDP細(xì)胞對(duì)順鉑的敏感性,并具有劑量依賴性。我們利用流式細(xì)胞術(shù)檢測(cè)了腫瘤細(xì)胞對(duì)熒光染料Rh-123吸收的變化,結(jié)果顯示,異長(zhǎng)春花堿水平越高,則胞內(nèi)Rh-123的含量越高。Rh-123是MDR1底物,胞內(nèi)Rh-123的含量提高可間接說明腫瘤細(xì)胞對(duì)化療藥物的外排作用降低。進(jìn)一步的WB和real-time PCR研究顯示,MDR1的蛋白和mRNA表達(dá)水平均下降,與Rh-123的研究結(jié)果一致。
除MDR1以外,凋亡相關(guān)基因也可以介導(dǎo)腫瘤細(xì)胞對(duì)順鉑的耐受。半胱天冬酶8(caspase-8)是細(xì)胞凋亡過程中的重要效應(yīng)物質(zhì),激活后可釋放到胞質(zhì)中啟動(dòng)caspase的級(jí)聯(lián)反應(yīng),激活下游的半胱天冬酶3(cas-pase-3),導(dǎo)致細(xì)胞凋亡。Bcl-2和survivin是腫瘤細(xì)胞中重要的凋亡抑制基因,已經(jīng)被證明在耐藥腫瘤細(xì)胞中過表達(dá),可通過阻斷凋亡終末效應(yīng)酶caspase-3活性抑制細(xì)胞凋亡。本研究的流式細(xì)胞分析結(jié)果顯示,異長(zhǎng)春花堿可促進(jìn)細(xì)胞的凋亡,并發(fā)現(xiàn)異長(zhǎng)春花堿可下調(diào)Bcl-2和survivin表達(dá),上調(diào)caspase-3/8表達(dá)。因此,我們認(rèn)為異長(zhǎng)春花堿是通過下調(diào)凋亡抑制基因,上調(diào)促凋亡基因表達(dá)實(shí)現(xiàn)對(duì)腫瘤細(xì)胞凋亡的調(diào)控作用。
PTEN是一種腫瘤抑制基因,可通過抑制Akt磷酸化,下調(diào)Akt活性,阻斷Akt下游信號(hào)轉(zhuǎn)導(dǎo)路徑及,調(diào)節(jié)下游基因表達(dá)[8,9]。我們發(fā)現(xiàn)異長(zhǎng)春花堿可上調(diào)PTEN表達(dá),抑制Akt磷酸化和NF-κB轉(zhuǎn)錄活性。Twist和Snail是NF-κB的下游靶基因,也是重要的促腫瘤轉(zhuǎn)錄因子,可通過調(diào)節(jié)下游基因在腫瘤耐藥產(chǎn)生過程中發(fā)揮重要作用,我們的結(jié)果也證明長(zhǎng)春花堿可下調(diào)Twist和Snail的轉(zhuǎn)錄活性。
綜上所述,我們認(rèn)為長(zhǎng)春花堿逆轉(zhuǎn)A549/DDP順鉑耐藥性可能與增加腫瘤細(xì)胞藥物蓄積,誘導(dǎo)凋亡有關(guān),調(diào)節(jié)PTEN/AKT/NF-κB信號(hào)路徑活性,進(jìn)而調(diào)節(jié)下游Twist和Snail等轉(zhuǎn)錄因子活性和耐藥相關(guān)基因表達(dá),可能是其作用機(jī)制的中心環(huán)節(jié)。